Chimeric antigen receptor (CAR) T‐cell therapy is a major advancement in the treatment of
lymphoid malignancies, especially diffuse large B‐cell lymphoma and acute lymphoblastic …

… antigen receptor (CAR) T cells refer to T cells that are genetically modified to express chimeric
antigen receptors. … Compared with T cell receptor (TCR) modified cells, CAR T cells have …

… We summarize the investigated antigens and generated CAR T cells both in preclinical and
clinical studies, discuss main challenges in the practical application of CAR T-cell therapy for …

Patient-reported outcomes (PROs) are an important tool to assess the impact of a new therapy
on symptom burden and health-related quality of life (HRQoL). Chimeric antigen receptor …

… transfer of genetically engineered chimeric antigen receptor (CAR) T … This presents both
challenges and opportunities from a … of systems biology to address key challenges in CAR T-cell …

… The use of chimeric antigen receptor T cells has been a very successful strategy in some …
art of CAR T cell therapy with special emphasis on the current challenges and opportunities. …

The success of chimeric antigen receptor T‐cell (CAR‐T) therapy in hematologic malignancies
has realized a longstanding effort toward harnessing the immune system to fight cancer …

… , summarize the common tumor-associated antigens in clinical trials of CAR-T cell therapy
for thoracic malignancies, and point out the current challenges and new strategies, aiming to …

… (BiTEs) and chimeric antigen receptors (CARs) for expression on cytotoxic T-cells 223 - 225
. CARs are single-chain variable fragment (scFv)-based receptors used to redirect T cells to …

… Chimeric antigen receptor is a fusion protein composed of extracellular … In this review, we
will mainly discuss the opportunities provided by CAR-modified NK cells and the challenges …